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ABSTRACT- Purpose. The primary objective of this study was to investigate the prevalence of 
clinically important potential drug-drug interactions (DDIs) in elderly patients attending the public 
primary health care system in Brazil. The secondary objective was to investigate possible predictors of 
potential DDIs. Methods. A cross-sectional study was carried out in 5 Brazilian cities located in the 
Ourinhos Micro-region, Sao Paulo State, between November 2010 and April 2011. The selected sample 
was divided according to the presence (exposed) or absence (unexposed) of one or more potential DDIs 
(defined as the presence of a minimum 5-day overlap in supply of an interacting drug pair). Data were 
collected from medical prescriptions and patients’ medical records. Potential DDIs (rated major or 
moderate) were identified using 4 DDI-checker programs. Logistic regression analysis was used to 
study potential DDI predictors. Results. The prevalence of clinically important potential DDIs found 
during the study period was 47.4%. Female sex (OR = 2.49 [95% CI 2.29–2.75]), diagnosis of  ≥ 3 
diseases (OR = 6.43 [95% CI 3.25–12.44]), and diagnosis of hypertension (OR = 1.68 [95% CI 1.23–
2.41]) were associated with potential DDIs. The adjusted OR increased from 0.90 [95% CI 0.82–1.03] 
in patients aged 60 – 64 years to 4.03 [95% CI 3.79 – 4.28] in those aged 75 years or older.  Drug 
therapy regimens involving  ≥ 2 prescribers (OR = 1.39 [95% CI 1.17–1.67]),  ≥ 3 drugs (OR = 3.21 
[95% CI 2.78–3.59]),  ≥ 2 ATC codes (OR = 1.19 [95% CI 1.12–1.29]),  ≥ 2 drugs acting on 
cytochrome P450 (OR = 2.24 [95% CI 2.07–2.46]), and ATC codes B (OR = 1.89 [95% CI 1.05–2.08]) 
and C (OR = 4.01 [95% CI 3.55–4.57]) were associated with potential DDIs. Conclusion. Special care 
should be taken with the prescription and therapeutic follow-up of patients who present characteristics 
identified as predictors. Knowledge of potential DDI predictors could aid in developing preventive 
practices and policies that allow public health services to better manage this situation. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see 
“For Readers”) may comment by clicking on ABSTRACT on the issue’s contents 
page. 
____________________________________________________________________________________ 
 
INTRODUCTION 
 
Earlier studies have reported that 54.4–80.0% 
of elderly Latin American outpatients presented 
with one or more potential drug-drug 
interactions (DDIs) (1,2), and the elderly 
population is increasing rapidly in Latin 
American countries (3). DDIs present 
deleterious outcomes, causing roughly 2.8% of 
all hospitalizations in older patients and 
representing an estimated cost of more than 
U$1 billion per year to health care systems (4-
6). Several factors influence the occurrence of 
potential DDIs in elderly patients (7-9). 
_____________________________________ 
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Knowledge of predictors of potential DDIs 
could aid in developing preventive practices 
and policies (9). However, to the authors’ 
knowledge, drug utilization studies analyzing 
these predictors in elderly patients at the 
primary health care level in Latin American 
countries are scarce.  
A previous drug utilization study conducted 
in a tertiary hospital setting in Brazil, a Latin 
American country, indicated that patient 
characteristics, prescriber characteristics, and 
drug characteristics influenced the occurrence 
of potential DDIs (8), but these findings cannot 
be extrapolated to the primary health care level. 
Up to 70.0% of Latin American patients are 
attended at the primary care level, reinforcing 
the need to study potential DDI predictors in 
this setting. 
The primary objective of this study was to 
investigate the prevalence of clinically 
important potential DDIs in elderly patients 
attending the public primary health care system 
in a south-eastern region of Brazil. The 
secondary objective was to investigate possible 
predictors of potential DDIs.    
 
METHODS 
 
Study design 
This study was approved by the Research 
Ethical Committee of the State University of 
Maringa, Brazil (CAAE 0010-10). The research 
followed a cross-sectional study model, with 
the selected sample group divided between 
patients receiving drug therapies with one or 
more potential DDI (exposed) and those 
receiving drug therapies with no potential DDI 
(unexposed). The study was carried out 
between November 2010 and April 2011, using 
data from the public primary health care system 
in 5 Brazilian cities located in the Ourinhos 
Micro-region, Sao Paulo State. The Ourinhos 
Micro-region has an estimated population of 
280,000 individuals (28,929 over the age of 60 
years), attended by 36 Basic Health Units 
(BHUs). Twenty-seven BHUs participated in 
the study. 
The Brazilian Public Health System 
provides free access to primary, secondary, and 
tertiary care to all inhabitants, including the 
supply of drugs by pharmacies located in health 
establishments. Primary care offered to 
outpatients in BHUs involves health education, 
prevention and surveys of disease spread, and 
drug dispensation. Family physicians, general 
practitioners, and nurses provide primary health 
care interventions (consultations, exams, 
education groups, and vaccinations), and 
pharmacies within BHUs provide patients with 
the drugs prescribed by these professionals.  
 
Inclusion and exclusion criteria 
According to the threshold set by the United 
Nations Programme on Ageing, patients aged 
over 60 years were considered elderly (10). The 
use of a cut-off of 60 years instead of 65 years 
augmented the sample size of the study. 
Patients ≥ 60 years of age with at least one 
prescription for 2 or more drugs (prescribed 
both within and across prescriptions) collected 
in participating BHU pharmacies were eligible 
for inclusion in the study. 
The Brazilian public health system does not 
employ software to create electronic drug 
prescriptions. Drug prescriptions are hand-
written by the physicians. According to 
Brazilian legislation, prescriptions must be 
signed and dated by the physician, legible, and 
written in ink, with no sign of tampering (e.g. 
different handwriting or written in different ink 
colours) or erasures (e.g. scribble and blots), to 
be considered valid (11). Exclusion criteria 
included signs of prescription tampering or 
erasure and illegibility.  
 
Data collection 
The Brazilian public primary health care system 
has no administrative prescription database. 
Thus, data collection was carried out by 
analyzing patients’ drug prescriptions and 
medical records. 
At the time of dispensing the medication, 
the employees of participating BHU pharmacies 
(51 employees) registered patient identification 
(name, date of birth, and sex) and 
complementary information (drug dispensation 
amount and date) in the prescriptions and 
retained them. Three researchers (NN, JV and 
GS) were responsible for weekly collection of 
these prescriptions and determination of those 
eligible for inclusion in the study. Information 
from eligible prescriptions (name, date of birth, 
sex, names of the drugs prescribed, amount of 
drug dispensed, prescribers’ identification, date 
of prescription, and date of dispensation) was 
collected and entered into an electronic 
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database developed for the purpose of this study 
to rapidly access and assess this information. 
All prescriptions were classified according to 
the first level of the Anatomical Therapeutic 
Chemical (ATC) classification system, as 
recommended by the World Health 
Organization (12). In this system, active 
substances are divided into different groups 
according to the organ or system on which they 
act and their therapeutic, pharmacological and 
chemical properties (12). The ATC codes (first 
level) are alimentary tract and metabolism 
(ATC code ‘A’), blood and blood-forming 
organs (ATC code ‘B’), cardiovascular system 
(ATC code ‘C’), dermatologicals (ATC code 
‘D’), genito urinary system and sex hormones, 
excluding sex hormones and insulins (ATC 
code ‘G’), antiinfectives for systemic use (ATC 
code ‘J’), antineoplastic and imm-
unomodulating agents (ATC code ‘L’), 
musculo-skeletal system (ATC code ‘M’), 
nervous system (ATC code ‘N’), antiparasitic 
products, insecticides and repellents (ATC code 
‘P’), respiratory system (ATC code ‘R’), 
sensory organs (ATC code ‘S’) and various 
(ATC code ‘V’). 
Each patient attended in a BHU has a 
personal medical record file, where family 
physicians, general practitioners, and nurses 
register general patient information 
(identification, date of birth, sex, diseases 
diagnosed, clinical and laboratory exam results) 
and the interventions carried out (drug 
prescription, alterations in prescribed drugs, 
laboratory exam requests, and specialist 
referrals). This information was also entered 
into our electronic database. The same 
researchers were involved in the collection of 
patients’ medical records and data collection 
from the prescriptions. 
Four other researchers (EF, TM, CL and 
GB) accessed the electronic database to search 
for potential DDIs by listing the drugs 
prescribed in single prescriptions and across 
successive prescriptions for the same patient 
with the presence of a minimum 5-day overlap 
in days’ supply for object and precipitant 
medications, based on prescription delivery 
dates irrespective of prescriber (13), in DDI-
checker software. Potential DDIs were 
identified using 4 DDI-checker programs 
(DrugDigest®, Drugs®, Micromedex®, and 
Medscape®) (14-17) to promote greater 
sensitivity in the survey (18). These 4 DDI-
checker programs have been widely used in 
previous published studies and represent the 
programs most used by Latin American 
pharmacists. The drug therapy regimen of each 
patient was typed and evaluated independently 
by the four researchers mentioned above using 
the 4 DDI-checker programs, to avoid possible 
mistakes in the typing and evaluation  process. 
Only potential DDIs rated as major or moderate 
by at least 3 of the 4 DDI-checker programs 
utilised were included in the analysis. 
Clinical relevance was defined according to 
the criteria used by the DDI-checker software 
programs, which considered the ‘potential’ of 
DDIs for both adverse event risk and lack of 
efficacy. All DDIs was classified as of major, 
moderate, or minor clinical relevance on the 
basis of potential clinical outcomes and type, 
quality, and relevance of supporting clinical and 
pharmacological documentation. ‘Major’ DDIs 
were defined as drug combinations that should 
be usually avoided or may potentially lead to 
serious clinical consequences, such as severe 
adverse effects or no clinical effects, and 
required close monitoring; ‘moderate’ as drug 
combinations where the precipitant drug may 
modify the effect of the object drug, but the 
resulting effect can be controlled by adjustment 
of individual doses and/or drug plasma 
concentration; and ‘minor’ as drug 
combinations likely to have no clinical 
relevance or not completely assessed. For each 
potential DDI, the software also provided 
information on the mechanism responsible for 
the interaction (if available), the clinical or 
pharmacological effect of the interaction, and 
advice on measures to control or manage the 
risk of interaction. 
Before beginning the study, agreement 
between the 4 DDI-checker programs was 
tested by entering 12 drug pairs described by 
Gagne et al. (9) as clinically important potential 
DDIs into each selected program. All the 
programs utilised identified all 12 pairs as 
major or moderate potential DDIs.   
  
Predictor factors 
Study of possible predictors of potential DDIs 
included patient characteristics and drug 
therapy characteristics. The following patient 
characteristics were analyzed: age, sex, number 
of diagnosed diseases, diagnosis of 
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hypertension, and diagnosis of diabetes. For 
each patient, the number of prescribers, number 
of drugs consumed, ATC code classification of 
the drug therapy, number of ATC codes per 
drug therapy, and number of drugs that act on 
cytochrome P450 (CYP450) per drug therapy of 
each patient were analyzed as drug therapy 
characteristics. 
The list of substrates, inducers and 
inhibitors of CYP450 available in the appendix 
section of Lexi-Comp's Drug Information 
Handbook with International Trade Names 
Index 2010-2011 was used to identify drugs 
that act on CYP450 (19). The drug therapy 
regimen of each patient was checked 
independently by four researchers (EF, TM, CL 
and GB), to avoid possible mistakes in the 
process of searching for drugs acting on 
CYP450. 
Before selecting the predictor factors, 
electronic searches of the published literature 
from 1990 to 2011 were conducted through 
EMBASE and MEDLINE databases to identify 
risk factors for potential DDIs verified in 
previous studies. The search strategy included 
the terms (alone and in combination) drug-drug 
interactions, elderly, pharmacoepidemiology, 
predictors, and risk. 
Most selected predictor factors were chosen 
in accordance with the results of previous 
studies (2,7-9,20-23). Diabetes diagnosis was 
also included in the analysis because this 
disease was the second most prevalent disease 
in the sample.   
 
STATISTICAL ANALYSIS 
 
Data were presented as the absolute and relative 
frequency, mean, standard deviation (SD), and 
95% confidence interval (CI), as appropriate. 
Chi-square tests were used for categorical 
variables, and independent sample Student t-
tests were used for quantitative variables. 
Logistic regression analysis was used to study 
predictors of potential DDIs, with adjustment 
for age and sex. Exposure to a potential DDI 
(Yes ⁄ No) was the dependent variable in the 
model. Each exposed individual was included 
in the logistic regression analysis only once, 
regardless of the number of potential DDIs to 
which he or she was exposed. Patient 
characteristics and drug therapy characteristics 
were incorporated into the model as 
independent variables. The results are shown as 
odds ratios (OR) with 95% CI. A P value < 0.05 
was considered statistically significant. 
Analyses were performed using Statistica 
(StatSoft, Sao Caetano do Sul, SP, Brazil) 
version 8.0 and JMP software (SAS, Cary, NC, 
USA) version 8.0.1. 
 
RESULTS 
 
General characteristics 
During the study period, 12,343 patients 
fulfilled the entrance criteria and met no 
exclusion criteria. The prevalence of clinically 
important potential DDIs found during the 
study period was 47.4%. Figure 1 illustrates the 
data collection flow throughout the study. 
Participants’ general characteristics are shown 
in Table 1. Elderly patients received 51,042 
drug prescriptions (28.8% of the overall 
177,437 prescriptions). More than 80.0% of 
elderly patients were exposed to at least one 
drug utilised to treat a chronic disease. 
Thiazide diuretics (72.9%) were the most 
frequently prescribed drugs in patients exposed 
to clinically important potential DDIs, followed 
by angiotensin-converting enzyme inhibitors 
(ACEI) (63.0%), digitalis glycosides (44.3%), 
platelet aggregation inhibitors excluding 
heparin (44.0%), and loop diuretics (31.0%). 
The 5 most widely prescribed therapeutic 
groups in patients unexposed to clinically 
important potential DDIs were beta-lactam 
antibacterials (penicillins) (49.0%), biguanides 
(23.0%), dihydropyridine-derivate calcium 
channel blockers (19.0%), analgesics (anilides) 
(16.0%), and thiazide diuretics (16.0%). 
 
Predictors of potential DDIs  
Univariate and multivariate analyses of patient 
characteristics indicated female sex, diagnosis 
of 3 or more diseases and diagnosis of 
hypertension to be associated with increased 
risk of potential DDIs. Both univariate and 
multivariate analyses show age to be associated 
with an  increasing risk of DDIs. The adjusted 
OR increased from 0.90 [95% CI 0.82–1.03] in 
patients aged 60 – 64 years to 4.03 [95% CI 
3.79 – 4.28] in those aged 75 years or older. No 
statistical association was observed in the 
multivariate analysis with respect to a diagnosis 
of diabetes (Table 2).  
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Figure 1. Flowchart of the data collection throughout the study. 
 
 
Table 1. General characteristics according to exposure to clinically important potential drug-drug interactions. 
Characteristic Exposed 
N = 5,855 
Unexposed 
N = 6,488 
P value 
Mean age (+SD) years 63.31 (3.47) 61.42 (2.25) <0.001 
Female sex, n (%) 4854 (82.9) 4163 (64.2) <0.001 
Mean number of prescribers (+SD) 1.05 (0.24) 1.03 (0.19) <0.001 
Mean number of drugs consumed (+SD) 2.94 (0.84) 2.25 (0.52) <0.001 
Mean number of ATC codes consumed 
(+SD) 
1.72 (0.65) 1.56 (0.53) <0.001 
ATC code ‘A’ (alimentary tract and 
metabolism) 
3116 (53.2) 1664 (25.6) <0.001 
ATC code ‘B’ (blood and blood-forming 
organs) 
2541 (43.4) 1082 (16.7) <0.001 
ATC code ‘C’ (cardiovascular system) 5641 (96.3) 2953 (45.5) <0.001 
ATC code ‘H’ (systemic hormonal 
preparations, excluding sex hormones and 
insulin) 
44 (0.7) 8 (0.1) <0.001 
ATC code ‘J’ (antiinfectives for systemic 
use) 
2834 (48.4) 3278 (50.5) 0.019 
ATC code ‘M’ (musculo-skeletal system) 1529 (26.1) 1843 (28.4) 0.005 
ATC code ‘N’ (nervous system) 1393 (23.8) 1540 (23.7) 0.965 
ATC code ‘R’ (respiratory system) 754 (12.9) 886 (13.7) 0.204 
Mean number of drugs acting on CYP450 
(+SD) 
2.12 (0.94) 1.63 (0.98) <0.001 
Mean number of diagnosed diseases (+SD) 1.61 (0.58) 1.55 (0.50) <0.001 
Hypertension, n (%) 5357 (91.5) 3468 (53.4) <0.001 
Diabetes, n (%) 3289 (56.2) 1454 (22.4) <0.001 
The chi-square test and the independent sample Student’s t-test were used as appropriate.  P values < 0.05 were 
considered statistically significant. 
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The number of prescribers, drugs 
consumed, ATC codes, and drugs that act on 
CYP450 presented positive associations with 
potential DDIs in univariate and multivariate 
analyses of drug therapy characteristics. ATC 
codes B and C were also predictors of potential 
DDIs. The univariate analysis further indicated 
ATC codes A and H and potential DDIs rated 
as major and moderate to be associated with 
increased risk of potential DDIs, but 
multivariate analysis did not confirm these 
associations. ATC codes J, N, M, and R 
presented no statistical association in either 
univariate or multivariate analysis (Table 3). 
 
 
Table 2. Patient characteristics associated with potential drug-drug interactions. 
Predictor factor Univariate analysis OR 
[95% CI] 
Multivariate analysis OR 
[95% CI]a 
P value 
Female sex 2.71 [2.49–2.95] 2.49 [2.29–2.75] <0.001 
Age (years)    
60 – 64 0.96 [0.85–1.04] 0.90 [0.82–1.03] 0.141 
65 - 69 2.02 [1.88 – 2.19] 1.66 [1.49 – 1.80] <0.001 
70 - 74 3.12 [3.00 – 3.31] 3.00 [2.85 – 3.10] <0.001 
> 75 4.21 [4.02 – 4.41] 4.03 [3.79 – 4.28] <0.001 
Number of diagnosed 
diseases ≥ 3 
26.38 [13.65–57.54] 6.43 [3.25–12.44] <0.001 
Diagnosis of hypertension 9.37 [8.44–10.39] 1.68 [1.23–2.41] <0.001 
Diagnosis of diabetes 4.44 [4.11–4.80] 1.04 [0.88–1.14] 0.153 
aAdjusted for age and sex. 
P values < 0.05 were considered statistically significant. 
 
 
 
Table 3. Drug therapy characteristics associated with potential drug-drug interactions. 
Predictor factor Univariate analysis OR 
[95% CI] 
Multivariate analysis 
OR [95% CI]a 
P value 
Number of prescribers ≥ 2 1.41 [1.18–1.70] 1.39 [1.17–1.67] <0.001 
Number of drugs consumed ≥ 3 6.40 [5.90–6.94] 3.21 [2.78–3.59] <0.001 
Number of ATC codes ≥ 2 1.50 [1.40–1.61] 1.19 [1.12–1.29] <0.001 
ATC code ‘A’ (alimentary tract 
and metabolism) 
3.30 [3.06–3.56] 1.07 [0.89–1.20] 0.005 
ATC code ‘B’ (blood and blood-
forming organs) 
3.83 [3.53–4.16] 1.89 [1.05–2.08] <0.001 
ATC code ‘C’ (cardiovascular 
system) 
31.56 [27.30–36.48] 4.01 [3.55–4.57] <0.001 
ATC code ‘H’ (systemic 
hormonal preparations, 
excluding sex hormones and 
insulin) 
6.13 [2.99–13.94] 1.01 [0.91–1.18] 0.667 
ATC code ‘J’ (antiinfectives for 
systemic use) 
0.92 [0.86–0.99] 0.91 [0.85–0.99] 0.148 
ATC code ‘M’ (musculo-skeletal 
system) 
0.89 [0.82–0.97] 0.83 [0.80–0.98] 0.051 
ATC code ‘N’ (nervous system) 1.00 [0.92–1.09] 0.91 [0.86–1.01] 0.149 
ATC code ‘R’ (respiratory 
system) 
0.93 [0.84–1.04] 0.91 [0.82–1.04] 0.149 
Number of drugs acting on 
CYP450 ≥ 2 
2.32 [2.12–2.53] 2.24 [2.07–2.46] <0.001 
aAdjusted for age, sex, number of chronic conditions, and number of drugs consumed. 
P values < 0.05 were considered statistically significant. 
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Clinically important potential DDIs 
During the study, patients were exposed to 
9,368 clinically important potential DDIs 
corresponding to 364 drug combinations. The 
mean number of DDIs per patient was 1.60 
(range 1–4), with nearly 13.0% of cases having 
2 or more DDIs. Most of potential DDIs 
identified were pharmacodynamic interactions 
(82.8%). Referent to clinical relevance, 33.4% 
of the potential DDIs identified were rated as 
major by at least 3 of the DDI-checker 
programs utilised. 
The 12 most frequently observed DDIs 
(Table 4) were responsible for 5,361 (57.2%) of 
all potential DDIs. As expected, cardiovascular 
drugs (hydrochlorothiazide, captopril, 
furosemide, digoxin, spironolactone, 
simvastatin, losartan, verapamil, amiodarone, 
atenolol, bezafibrate, and diltiazem) and drugs 
affecting blood clotting (acetylsalicylic acid, 
ticlopidine, and warfarin) were the most 
frequently involved. Of the 413 active 
substances prescribed to exposed patients, 
31.0% were responsible for potential DDIs. 
The 9,368 clinical important potential DDIs 
corresponded to 364 drug combinations. 
However, the first 12 (Table 4) were 
responsible for 5,361 (57.2%) of all potential 
DDIs. 
 
DISCUSSION 
 
To the authors’ knowledge, this investigation is 
the first cross-sectional study conducted in the 
public primary health care system of a Latin 
American country to assess the prevalence of 
clinically important potential DDIs and to 
investigate possible predictors of potential 
DDIs in elderly outpatients. 
Knowledge of the prevalence and predictors 
of clinically important potential DDIs will help 
physicians and pharmacists identify patients at 
higher risk of DDI-related adverse drug 
reactions, who require more cautious 
pharmacotherapy management to avoid 
negative outcomes. 
 
 
 
 
Table 4. Most common potential drug-drug interactions 
Drug combinationa N (%) Possible clinical 
consequencesa 
Clinical relevanceb
Digoxin and Furosemide/ 
Hydrochlorothiazide 
2533 (43.3) Digitalis toxicity Moderate 
Captopril/Losartan and 
Spironolactone 
1020 (17.4) Hyperkalemia Major 
Acetylsalicylic acid and 
Ticlopidine 
324 (5.5) Bleeding and 
gastrointestinal lesions 
Moderate 
Amiodarone and 
Spironolactone 
252 (4.3) Ventricular arrhythmias Moderate 
Amitriptyline and Fluoxetine 203 (3.5) Amitriptyline toxicity Major 
Acetylsalicylic acid and 
Warfarin 
201 (3.4) Bleeding and 
gastrointestinal lesions 
Major 
Verapamil and Atenolol 167 (2.8) Bradycardia, sinus and 
atrioventricular depression 
Major 
Amitriptyline and Diazepam 150 (2.6) Excessive or prolonged 
CNSc and respiratory 
depression 
Moderate 
Omeprazole and Simvastatin 148 (2.5) Myopathy Moderate 
Amiodarone and Simvastatin 127 (2.2) Myopathy and 
rhabdomyolysis 
Major 
Bezafibrate and Simvastatin 127 (2.2) Myopathy and 
rhabdomyolysis 
Major 
Diltiazem and Simvastatin 109 (1.9) Myopathy Major 
aDrugDigest®, Drugs®, Micromedex® and Medscape® were used to identify potential DDIs and their possible 
clinical consequences. 
bClinical relevance classified according to 3 or more DDI-checker programs utilised.  
cCNS: central nervous system. 
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The patient characteristics such as female sex, 
more advanced age, diagnosis of hypertension, 
and greater number of diagnosed diseases were 
identified as predictors of potential DDIs. A 
large numbers of prescribers, drugs consumed, 
ATC codes, and drugs acting on CYP450 were 
verified as drug therapy-related predictors of 
potential DDIs. The present results further 
indicated that ATC codes B and C codes were 
predictors of potential DDIs. 
In some situations, changing some drugs 
utilised by a patient is possible and can lead to 
safer drug therapy regimens. However, a huge 
number of clinically important potential DDI 
identified cannot be avoided in some situations. 
For example, congestive heart failure patients 
with atrial fibrillation receive drug therapy that 
includes ACEI, furosemide, spironolactone, and 
digoxin, despite the potential risk for DDIs. 
More cautious drug therapy management in this 
situation is extremely important to guarantee 
patient safety, especially in patients presenting 
other predictor of potential DDI.  
 
Patient characteristic predictors 
Consistent with the findings of previous drug 
utilization studies, older patients presented 
higher odds of exposure to potential DDIs in the 
present study. A study of outpatients in 
Thailand found that the risk of having at least 
one potential DDI increased with patient age 
(7). A significantly increased odds ratio was 
also reported by Cruciol-Souza et al. in patients 
≥55 years in a Brazilian hospital (8). In studies 
of Italian outpatients, patients aged 65–74, 75–
84, and ≥85 years showed increasing odds for 
exposure to potential DDIs (9), and the adjusted 
OR rose from 1.07 [CI95% 1.03–1.11] in 
patients aged 70–74 years to 1.52 [CI95% 1.46–
1.60] in those aged ≥85 years (20). The 
prevalence of potential DDIs increased linearly 
with increasing age (P < 0.001) in a study of 
outpatients in Taiwan (24). A relationship 
between age and potential DDIs was also 
reported in a Danish outpatient population, with 
the risk of DDIs rising from 24.0% in 
individuals aged 60–79 years to 36.0% in those 
over 80 (25). These results can be attributed to 
the increased complexity of drug therapy 
regimens found in older adults, which result in 
a higher prevalence of potential DDIs (7). 
The present results indicated that the female 
sex was associated with the occurence of 
potential DDIs. Published results concerning 
the influence of sex on potential DDI 
occurrence are variable. Cruciol-Souza et al. 
identified female sex as a predictor of potential 
DDIs in hospitalised Brazilian patients (8). 
Higher risks for potential DDIs in females were 
also reported by Costa et al. in a family practice 
centre in the USA (21). However, equal rates of 
potential DDIs in prescriptions for male and 
female outpatients were reported in the study 
conducted by Janchawee et al. in Thailand (7). 
Unlike the findings of our study, the results 
obtained by Johnell et al. showed a lower 
probability of potentially serious DDIs in 
female elderly Swedish outpatients (26). No 
statistically significant association was verified 
with respect to sex in studies conducted by 
Nobili et al. (20) Gagne et al. (9) with 
outpatients in Italy. This inconsistency in the 
results could stem from several factors, 
including differences in patient health status, 
study settings, sources used to identify potential 
DDIs, culture, and prescribing habits. 
In the present study, the odds for potential DDI 
exposure were associated with a higher number 
of diagnosed diseases and diagnosis of 
hypertension. Costa et al. verified a higher 
relative risk in patients with a diagnosis of 3 or 
more diseases (21). Patients diagnosed with 
cardiovascular diseases were predictors for 
potential DDIs in a study conducted in family 
medicine clinics in Mexico (2). 
 
Drug therapy predictors 
Prescription of drug therapy regimens by 2 or 
more prescribers was associated with the 
occurrence of potential DDIs in the present 
study. This result was similar to that reported 
by Cruciol-Souza et al., who found an 
association between multiple prescribers and 
potential DDI occurrence in a Brazilian hospital 
(8). This finding may be due to gaps in 
communication and coordination across 
multiple prescribers for the same patient (27). 
The present results also support the findings 
of previous drug utilization studies 
demonstrating that a larger number of drugs 
consumed and ATC codes were associated with 
the occurrence of potential DDIs. Costa et al. 
verified the elevated relative risk for patients 
using more than 3 drugs in a family practice 
centre in the USA (21). Prescriptions containing 
more than 6 drugs and more than 2 ATC codes 
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were associated with the occurrence of potential 
DDIs in a Brazilian hospital (8). Doubova-
Dubova et al. reported a significant association 
between drug therapy regimens of 5 or more 
drugs and having one or more potential DDIs 
(2). An association between the number of 
drugs prescribed and the occurrence of potential 
DDIs was also observed by Gagne et al. (9). 
The adjusted OR rose from 2.71 [95% CI 2.63–
2.80] in patients using 3–5 drugs for chronic 
diseases to 5.59 [95% CI 5.39–5.80] in those 
using 6 or more drugs, in another study of 
outpatients in Italy (20). The mean number of 
drugs prescribed to Thai outpatients with 
potential DDIs was 5.8 ± 2.4, with a positive 
association between potential DDIs and 
increasing number of drugs consumed (24). A 
strong association between number of 
dispensed drugs and the probability of potential 
DDIs was also reported among outpatients in 
Sweden after adjustment for age and sex (26). 
With respect to the influence of ATC codes 
in the occurrence of potential DDIs, no 
consensus is apparent among published results. 
In the present study, ATC codes B and C were 
associated with the occurrence of potential 
DDIs. Cruciol-Souza et al. also reported ATC 
codes B and C as predictors of potential DDIs 
(8). However, in contrast to the present results, 
they also found ATC codes S and J to be 
predictors of potential DDIs (8). This difference 
could be due to differences in health status 
between outpatients and hospitalised patients 
leading to different prescription characteristics. 
In the present study, larger numbers of 
drugs that act on CYP450 were associated with 
the occurrence of potential DDIs. In another 
study conducted in Brazil, Cabrera et al. found 
that elderly outpatients used high levels of 
drugs that act on CYP450 (61.6%), thereby 
increasing the risk of potential DDIs in a group 
that is already vulnerable to adverse drug 
effects (28). This finding is of wide concern, 
because diseases frequently observed in elderly 
patients lead to hepatic metabolism changes, 
increasing the risk of negative outcomes 
associated with the use of these drugs (29,30). 
The most frequently prescribed drugs 
affecting CYP450 were benzodiazepines, 
tricyclic antidepressants, non-steroidal anti-
inflammatory drugs (NSAIDs), anti-histamines, 
and selective serotonin reuptake inhibitors. 
These drugs are considered potentially 
inappropriate for the elderly due to their 
toxicity or low efficiency (31). Previous drug 
utilization studies have also verified the high 
prevalence for prescriptions of potentially 
inappropriate drugs for the elderly (32,33). 
Cardiovascular drugs were predominant 
among potential DDIs in the present study. 
Cruciol-Souza et al. also identified 
cardiovascular drugs as the most frequently 
involved in potential DDIs (8). However, in a 
study conducted in Thailand, anti-infective 
drugs were involved in the majority of potential 
DDIs (34). Doubova-Dubova et al. reported 
NSAIDs as the most frequently involved drug 
in potential DDIs (2). This variation in 
published results may be due to several factors 
including differences in study setting, patient 
health status, assessment criteria for DDIs, 
sources for identifying potential DDIs, culture, 
and prescribing habits. 
 
Limitations 
The utilization of DDI-checker software 
provides only a ‘potential’ estimate of DDI 
occurrence. This approach cannot take into 
account whether the potential DDI produced an 
adverse event or negatively influenced the 
therapeutic effect of a drug. Furthermore, the 
definition of ‘clinical relevance’ according to 
the rating system of DDI-checker software does 
not take into account what intervention a 
clinician may use (dosage adjustment, 
laboratory or clinical monitoring) to avoid a 
potential adverse effect or to reduce DDI risk. 
However, despite these limitations, this 
approach is currently widely used to assess the 
clinical relevance and risk of exposure to 
potential DDIs (35). 
The lack of consensus between various 
sources available to analyze potential DDIs, 
with different classifications of severity and 
clinical importance (36), also poses a challenge 
to potential DDI assessment studies. The 
present study utilised several sources to 
minimise this potential bias. The risk of 
interactions may be underestimated due to the 
limitations in the majority of instruments 
available for assessing the probability of DDIs, 
which consider only single pairs of drugs and 
do not account for interactions involving 
combinations of 3 or more drugs (37,38). Most 
of also do not account for the dosages or 
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duration of therapies or individual patient risk 
factors. 
In addition, drugs prescribed to the sample 
group in other health settings were not included 
in the evaluation, which may underestimate the 
occurrence of potential DDIs. Furthermore, 
non-prescribed drugs including over-the-
counter products, herbal remedies, and 
nutritional supplements were not considered, 
preventing us from assessing potential DDIs 
between these products and prescription drugs 
(39).   
 
CONCLUSION 
 
The results of this large population-based study 
indicated a significant prevalence of clinically 
important potential DDIs in elderly outpatients. 
Patient characteristics including female sex, 
increased age, diagnosis of multiple diseases, 
and diagnosis of hypertension were predictors 
of potential DDIs in the population studied. 
With respect to drug therapy regimens, larger 
numbers of prescribers, drugs prescribed, ATC 
codes, and drugs that act on CYP450 increased 
the risk for potential DDI occurrence. ATC 
codes B and C were also predictors for potential 
DDIs. By providing information on patient and 
drug therapy characteristics that increase the 
risk of potential DDIs in elderly patients in a 
primary care setting, these results could help in 
the development of prescribing and therapeutic 
follow-up guides.  
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